Vaccine composition comprising hepatitis B virus like particle as adjuvant

Patent metadata

Field	Value
Publication number	US-11116837-B2
Application number	US-201716463357-A
Country	US
Kind code	B2
Filing date	Nov 22, 2017
Priority date	Nov 22, 2016
Publication date	Sep 14, 2021
Grant date	Sep 14, 2021

Abstract

The present disclosure provides vaccine compositions and methods for inducing a systemic immune response and a mucosal immune response, wherein the vaccine compositions include an antigen and a hepatitis B core virus-like particle (HBc VLP) as an adjuvant. The vaccine compositions are suitable for administration to the mucosal surface of a subject, and are effective in eliciting a protective immune response against infection.

First claim

What is claimed is:

1. A vaccine composition comprising an antigen and an adjuvant, wherein the adjuvant is a hepatitis B core virus-like particle (HBc VLP) having an amino acid sequence at least 80% identical to an amino acid sequence of SEQ ID NO: 1 and having the same function as SEQ ID NO: 1, and wherein the antigen is derived from respiratory syncytial virus (RSV).

2. The vaccine composition of claim 1 , wherein the adjuvant is the HBc VLP consisting of the amino acid sequence of SEQ ID NO: 1.

3. The vaccine composition of claim 1 , wherein the antigen is a recombinant RSV F protein represented by one of SEQ ID NOs: 2 to 4.

4. The vaccine composition of claim 1 , wherein the adjuvant is present in an adjuvant-effective amount of 0.1 μg to 1000 μg.

5. The vaccine composition of claim 1 , having a weight ratio of the antigen to the adjuvant from 10:1 to 1:10.

6. The vaccine composition of claim 5 , wherein the weight ratio of the antigen to the adjuvant is from 5:1 to 1:5.

7. The vaccine composition of claim 1 , being suitable for mucosal vaccination.

8. The vaccine composition of claim 1 , being suitable for oral, nasal, rectal, or vaginal application.

9. The vaccine composition of claim 1 , inducing a mucosal immune response and a systemic immune response, wherein the mucosal immune response is antigen-specific secretory IgA antibody production, and the systemic immune response is antigen-specific IgG antibody production and antigen-specific cell-mediated immune production.

10. A method of vaccinating a subject, comprising administering the vaccine composition of claim 1 to a mucosal surface of the subject.

11. The method of claim 10 , wherein the mucosal surface is selected from the group consisting of respiratory, gastrointestinal, vaginal, nasal, rectal and oral mucosa.

12. The method of claim 10 , wherein the subject is human or animal.

Assignees

• Univ Nat Taiwan

Inventors

• Huang Limin
• Huang Jenmin

Classifications

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K2039/55588

  Adjuvants of undefined constitution · CPC title

• A61K2039/541

  Mucosal route · CPC title

• A61K2039/5258

  Virus-like particles · CPC title

• C12N2730/10134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title